Compare BELFB & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BELFB | CRNX |
|---|---|---|
| Founded | 1949 | 2008 |
| Country | United States | United States |
| Employees | 4964 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.9B |
| IPO Year | N/A | 2018 |
| Metric | BELFB | CRNX |
|---|---|---|
| Price | $254.51 | $36.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $174.25 | $76.75 |
| AVG Volume (30 Days) | 250.0K | ★ 1.3M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.11% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,039,000.00 |
| Revenue This Year | $9.74 | $720.10 |
| Revenue Next Year | $6.34 | $184.67 |
| P/E Ratio | $42.80 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $70.87 | $25.83 |
| 52 Week High | $308.27 | $57.99 |
| Indicator | BELFB | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 46.66 | 44.09 |
| Support Level | $241.14 | $33.19 |
| Resistance Level | $308.27 | $37.23 |
| Average True Range (ATR) | 14.22 | 2.32 |
| MACD | -6.15 | -0.44 |
| Stochastic Oscillator | 14.01 | 25.18 |
Bel Fuse Inc designs and manufactures electronic components that protect and connect electronic circuits. Its product portfolio is divided into three categories: magnetic solutions, power solutions & protection, and connectivity solutions. These products are used for the computer, networking, telecommunications, transportation and defense/aerospace, automotive, medical, and consumer electronics industries. Its geographical segments are the United States, Macao, United Kingdom, Slovakia, Germany, Switzerland, and All other foreign countries. Majority of the revenue is derived from United States.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.